Literature DB >> 22972196

Models of bone metastasis.

J Preston Campbell1, Alyssa R Merkel, S Kathryn Masood-Campbell, Florent Elefteriou, Julie A Sterling.   

Abstract

Bone metastases are a common occurrence in several malignancies, including breast, prostate, and lung. Once established in bone, tumors are responsible for significant morbidity and mortality. Thus, there is a significant need to understand the molecular mechanisms controlling the establishment, growth and activity of tumors in bone. Several in vivo models have been established to study these events and each has specific benefits and limitations. The most commonly used model utilizes intracardiac inoculation of tumor cells directly into the arterial blood supply of athymic (nude) BalbC mice. This procedure can be applied to many different tumor types (including PC-3 prostate cancer, lung carcinoma, and mouse mammary fat pad tumors); however, in this manuscript we will focus on the breast cancer model, MDA-MB-231. In this model we utilize a highly bone-selective clone, originally derived in Dr. Mundy's group in San Antonio, that has since been transfected for GFP expression and re-cloned by our group. This clone is a bone metastatic variant with a high rate of osteotropism and very little metastasis to lung, liver, or adrenal glands. While intracardiac injections are most commonly used for studies of bone metastasis, in certain instances intratibial or mammary fat pad injections are more appropriate. Intracardiac injections are typically performed when using human tumor cells with the goal of monitoring later stages of metastasis, specifically the ability of cancer cells to arrest in bone, survive, proliferate, and establish tumors that develop into cancer-induced bone disease. Intratibial injections are performed if focusing on the relationship of cancer cells and bone after a tumor has metastasized to bone, which correlates roughly to established metastatic bone disease. Neither of these models recapitulates early steps in the metastatic process prior to embolism and entry of tumor cells into the circulation. If monitoring primary tumor growth or metastasis from the primary site to bone, then mammary fat pad inoculations are usually preferred; however, very few tumor cell lines will consistently metastasize to bone from the primary site, with 4T1 bone-preferential clones, a mouse mammary carcinoma, being the exception. This manuscript details inoculation procedures and highlights key steps in post inoculation analyses. Specifically, it includes cell culture, tumor cell inoculation procedures for intracardiac and intratibial inoculations, as well as brief information regarding weekly monitoring by x-ray, fluorescence and histomorphometric analyses.

Entities:  

Mesh:

Year:  2012        PMID: 22972196      PMCID: PMC3490264          DOI: 10.3791/4260

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

Review 1.  Advances in the biology of bone metastasis: how the skeleton affects tumor behavior.

Authors:  Julie A Sterling; James R Edwards; T John Martin; Gregory R Mundy
Journal:  Bone       Date:  2010-07-17       Impact factor: 4.398

2.  TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.

Authors:  Rachelle W Johnson; Mai P Nguyen; Susan S Padalecki; Barry G Grubbs; Alyssa R Merkel; Babatunde O Oyajobi; Lynn M Matrisian; Gregory R Mundy; Julie A Sterling
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

3.  Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction.

Authors:  Lindsay C Johnson; Rachelle W Johnson; Steve A Munoz; Gregory R Mundy; Todd E Peterson; Julie A Sterling
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

4.  The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells.

Authors:  Julie A Sterling; Babatunde O Oyajobi; Barry Grubbs; Susan S Padalecki; Steve A Munoz; Anjana Gupta; Beryl Story; Ming Zhao; Gregory R Mundy
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Authors:  Xin Lu; Euphemia Mu; Yong Wei; Sabine Riethdorf; Qifeng Yang; Min Yuan; Jun Yan; Yuling Hua; Benjamin J Tiede; Xuemin Lu; Bruce G Haffty; Klaus Pantel; Joan Massagué; Yibin Kang
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

6.  Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Authors:  Xiaohong Li; Julie A Sterling; Kang-Hsien Fan; Robert L Vessella; Yu Shyr; Simon W Hayward; Lynn M Matrisian; Neil A Bhowmick
Journal:  Mol Cancer Res       Date:  2012-01-30       Impact factor: 5.852

7.  GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice.

Authors:  Markus Steinbauer; Markus Guba; Grigore Cernaianu; Gudrun Köhl; Michaela Cetto; Leoni A Kunz-Schughart; Edward K Geissler; Werner Falk; Karl-Walter Jauch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  Osteoactivin promotes breast cancer metastasis to bone.

Authors:  April A N Rose; François Pepin; Caterina Russo; Jad E Abou Khalil; Michael Hallett; Peter M Siegel
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

Review 10.  Osteolytic bone metastasis in breast cancer.

Authors:  T Yoneda; A Sasaki; G R Mundy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more
  52 in total

1.  Adipogenic niches for melanoma cell colonization and growth in bone marrow.

Authors:  Juan Wang; Guang-Liang Chen; Shan Cao; Ming-Chun Zhao; Yong-Qing Liu; Xiao-Xiang Chen; Cheng Qian
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

2.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

3.  Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.

Authors:  Colton Hanna; Letty Kwok; Jessica Finlay-Schultz; Carol A Sartorius; Diana M Cittelly
Journal:  J Vis Exp       Date:  2016-11-30       Impact factor: 1.355

Review 4.  Breast Cancer Dormancy in Bone.

Authors:  Miranda E Clements; Rachelle W Johnson
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

5.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

6.  Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio).

Authors:  Eric B Berens; Ghada M Sharif; Anton Wellstein; Eric Glasgow
Journal:  J Vis Exp       Date:  2016-11-03       Impact factor: 1.355

7.  Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.

Authors:  Denise Buenrostro; Kristin A Kwakwa; Nicole E Putnam; Alyssa R Merkel; Joshua R Johnson; James E Cassat; Julie A Sterling
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

8.  Development of Raman spectral markers to assess metastatic bone in breast cancer.

Authors:  Hao Ding; Jeffry S Nyman; Julie A Sterling; Daniel S Perrien; Anita Mahadevan-Jansen; Xiaohong Bi
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

9.  Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy.

Authors:  Xiaohong Bi; Julie A Sterling; Alyssa R Merkel; Daniel S Perrien; Jeffry S Nyman; Anita Mahadevan-Jansen
Journal:  Bone       Date:  2013-07-15       Impact factor: 4.398

10.  Runx2-Smad signaling impacts the progression of tumor-induced bone disease.

Authors:  Xuhui Zhang; Jacqueline Akech; Gillian Browne; Stacey Russell; John J Wixted; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Int J Cancer       Date:  2014-08-05       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.